Post Tagged with: "Drug Licencing"

Tuberous Sclerosis Complex and Drug Licensing

Constituents have expressed concern about the availability of Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex. NHS England have decided not to consider this treatment for routine commissioning this year. The overall budget for specialised services in England is considerable, at around £15.7 billion per year. NHS England […]

Read More